Effect of Propranolol, Barbiturate Anesthesia and Splenectomy on Factor VIII: C and Plasminogen Activator Release Induced by DDAVP

Summary

After the injection of DDAVP in 39 non-anaesthezised dogs (0.4 μg/kg) factor VIII: C activity rose to 145% of baseline values (p <0.0001) and the fibrinolytic potential of euglobulin precipitate rose to 196% (p <0.0001). The injection of DDAVP was repeated three times in each dog of a group of good responder animals at weekly intervals, but after: A) Pentobarbital anesthesia (30 mg/kg) - the increase of factor VIII: C was reduced from 164% to 116% (n = 11; p <0.0005) and the increase in fibrinolytic activity was reduced from 270% to 192% (n = 11; p <0.05). B) Injection of propranolol (1 mg/kg) - the increase of factor VIII :C was reduced from 167% to 110% (n = 13; p <0.0005) and there was no significant decrease of fibrinolytic activity (n = 13; n.s.). C) Splenectomy - the increase of factor VIII: C was reduced from 166% to 122% (n = 10; p <0.0005) and fibrinolytic activity was not significantly changed from 196% to 256% (n = 9; n.s.). There were no statistically significant differences in the increases of factor VIII :C and fibrinolytic potential of euglobulin precipitate after repeating only the injection of DDAVP three times in the same animal at weekly intervals (n = 5; n.s.). We conclude that the increases in factor VIII: C and fibrinolytic activities observed after DDAVP infusion in the dog are due to different mechanisms of action. Pentobarbital anesthesia reduced the increase of factor VIII: C and fibrinolytic activity, but on the other hand, beta-blockade and splenectomy influenced differently the behaviour of both biological activities.

Injection of the synthetic analogue of vasopressin 1-deamino-8-d-arginine vasopressin (DDAVP) increases the plasma levels of factor VIII procoagulant activity (factor VIII: C) and plasminogen activator both in man and dog (1, 2, 3, 4).

The mechanism of action of DDAVP in determining these responses is not well known. In this work, after having confirmed that DDAVP increases factor VIII: C and fibrinolytic activity in the blood of the unanaesthezised dog, and in order to clarify the mechanisms involved in these pharmacological effects, we repeated the DDAVP injection in animals previously submitted to propranolol, pentobarbital anesthesia and splenectomy.

Keywords

DDAVP - Factor VIII: C - Fibrinolytic activity - Spleen - Anesthesia - Propranolol

• References

• 1 Cash JD, Gader AM A, Da Costa J. The release of plasminogen activator and factor VIII: C to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man. Br J Haematol 1974; 27: 363-364
• 2 Mannucci PM, Aberg M, Nilsson IM. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81
• 3 Prowse CV, Dow RC, Sheward WJ, Fink G, Boulton FE. The plasminogen activator response to drug infusion and to direct hypotalamic stimulation in dogs and rats. In: Progress in Fibrinolysis. Davidson JF. et al. (ed) Churchill Livingstone; Edinburgh: 1983. (; VI). 104-106
• 4 Cort JH, Fishman AJ, Dodds WJ, Rand JH, Schwartz IL. New category of vasopressin receptor in the central nervous system: Evidence that this receptor mediates the release of a humoral factor VUI-mobilizing principle. Int J Pept Protein Res 1981; 17: 14-22
• 5 Biggs R. Human Blood Coagulation, Haemostasis and Thrombosis. Blackwell Scientific Publications; Oxford: 1972
• 6 Nilsson IM, Hedner V, Pandolfi M. The measurement of fibrinolytic activities. In: Fibrinolytics and Antifibrinolytics. Markwardt F. (ed) Springer-Verlag; New York: 1978: 107-134
• 7 Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VHI/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand’s disease. Br J Haematol 1981; 47: 283-293
• 8 Vicente V, Alberca I, Mannucci PM. Reduced effect of exercise and DDAVP on factor VUI-von Willebrand factor and plasminogen activator after sequential application of both the stimuli. Thromb Haemostas 1984; 51: 129-130
• 9 Booyse FM, Osikwicz G, Feder S. Effects of various agents on ristocetin-Willebrand factor activity in long-term cultures of von Willebrand and normal human umbilical vein endothelial cells. Thromb Haemostas 1981; 46: 668
• 10 Tuddenham EG, Lazarchick J, Hoyer L. Synthesis and release of factor VIII by cultured human endothelial cells. Br J Haematol 1981; 47: 617-626
• 11 Moffat EH, Giddings JC, Bloom AL. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusion on factor VIII and possible endothelial cell related activities. Br J Haematol 1984; 57: 651-662
• 12 Colucci M, Stassen JM, Salwa J, Collen D. Identification of plasminogen activator releasing activity in the neurohypophysis. Br J Haematol 1984; 58: 337-346
• 13 Gunn CG, Hampton JW. CNS influence on plasma levels of factor VIII activity. Am J Physiol 1967; 212: 124-130
• 14 Johnstone IB, Crane S. Failure of sodium pentobarbital anesthesia to alter l-desamino-8-D-arginine vasopressin-induced elevations of plasma factor VIH/von Willebrand factor in normal dogs. Can J Vet Res 1988; 52: 416-418
• 15 Pina-Cabral JM, Rodrigues C. Blood catecholamines levels, factor VIII and fibrinolysis after therapeutic electroshock. Br J Haematol 1974; 28: 371-380
• 16 Egeberg O. Changes in the activity of antihaemophilic factor (FVIII) and in the bleeding time associated with muscular exercise and adrenalin. Scand J Clin Lab Invest 1963; 15: 539-544
• 17 Pina-Cabral JM. Experimental haemorrhagic shock and factor VIII. Proc. 10th Congress European Society of Haematology. Karger, Basel: Strasbourg; 1965. Part ii 1030-1034
• 18 Cohen RJ, Epstein SE, Cohen LS, Dennis LH. Alterations of fibrinolysis and blood coagulation induced by exercise, and the role of beta-adrenergic-receptor stimulation. Lancet 1968; 2: 1264-1266
• 19 Ingram GI C, Jones VR. The rise in clotting factor VIII induced in man by adrenalin: effect of α- and β-blockers. J Physiol 1966; 187: 447-454
• 20 Cash JD, Woodfield DG, Allan AGE. Adrenergic mechanisms in the systemic plasminogen activator. Response to adrenaline in man. Br J Haematol 1970; 18: 487-494
• 21 Brommer EJ P, Derkx FH M, Barrett-Bergshoeff MM, Schalekamp MA D H. The inability of propranolol and aspirin to inhibit the response of fibrinolytic activity and factor VIII antigen to infusion of DDAVP. Thromb Haemostas 1984; 51: 42-44
• 22 Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-desamino-8-D-arginine yasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand’s disease. Lancet i 1977; 869-872
• 23 Takahashi H. Studies on the pathophysiology and treatment of Von Willebrand’s disease. Properties of Factor VIII after DDAVP infusion in variant Von Willebrand’s disease. Thromb Res 1981; 21: 357-365
• 24 Webster WP, Zukoski CF, Hutchin P, Reddick RI, Mandel SR, Penick GD. Plasma factor VIII synthesis and control as revealed by canine organ transplantation. Am J Physiol 1971; 220: 1147-1154
• 25 Webster WP, Dodds J, Mandel SR, Penick D. Biosynthesis of Factors VIII and IX: Organ Transplantation and Perfusion Studies. In: Handbook of Hemophilia. Brinkhous KM. (ed) Excerpta Medica; Amsterdam: 1975. (; I). 149-163
• 26 Mckee PA, Coussons RT, Buckner RG, Williams GR, Hampton JW. Effects of the spleen on canine factor VIII levels. J Lab Clin Med 1970; 75: 391-402
• 27 Wion KL, Kelly D, Summerfield JA, Tuddenham EG D, Lawn RM. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985; 317: 726-732
• 28 Rizza CR, Eipe J. Exercise factor VIII and the spleen. Br J Haematol 1971; 20: 629-634
• 29 Libre EP, Cowan DH, Watkins Jr SP, Shulman NR. Relationship between spleen, platelets and factor VIII levels. Blood 1968; 31: 358-368
• 30 Garcia VV, Coppola R, Mannucci PM. The role of the spleen in regulating the plasma levels of factor VUI-von Willebrand’s factor after DDAVP. Blood 1982; 60: 1402-1406
• 31 Kobayashi I, Ito M, Shibata A, Shinada S, Tsukada T. DDAVP in hemophilia B. Lancet 1978; 1: 615